Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04035200 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation
A Phase 2 study, sponsored by Imbrium Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT04035200 is a Phase 2 study that has completed, run by Imbrium Therapeutics. The registered enrollment target is 114 participants.
The verdict
NCT04035200, a Phase 2 study, has completed, sponsored by Imbrium Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with alcohol use disorder (AUD) who experience insomnia associated with alcohol cessation, compared to placebo.
Interventions
- DRUG Placebo
- DRUG V117957 tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2020-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04035200
The ClinicalTrials.gov registry entry for NCT04035200 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Imbrium Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04035200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04035200 about?
NCT04035200 is a clinical study titled "Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation". The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with alcohol use disorder (AUD) who experience insomnia associated with alcohol cessation, compared to placebo.
What is the current status of trial NCT04035200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2019-09-23. Estimated completion is 2020-11-06.
What interventions are being tested in trial NCT04035200?
The interventions under investigation include: Placebo (DRUG), V117957 tablets (DRUG).
Who is sponsoring clinical trial NCT04035200?
This trial is sponsored by Imbrium Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.